At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 602 enrolled
Drug / intervention
Esomeprazole +2 moredrug
Likely dose
Esomeprazole 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicentre, Randomised, Double-blind, Parallel-group, Comparative Study to Compare the Efficacy and Safety of Esomeprazole 20 mg and 40 mg Once Daily Oral Administration With Omeprazole 20 mg Once Daily Oral Administration in Patients With Reflux Esophagitis
In Brief
A Phase 3 clinical trial evaluating Esomeprazole and Omeprazole for Reflux Esophagitis. Completed, enrolled 602 participants across 41 sites.
Detailed Summary
This study is to evaluate the efficacy of esomeprazole 20 mg once daily and 40 mg once daily for 8 weeks on healing of Reflux Esophagitis in patients with reflux esophagitis in comparison with omeprazole 20 mg once daily by assessment of presence/absence of Reflux Esophagitis at Week 8 according to the Los Angeles classification .
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsReflux Esophagitis
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2007
First PostedMar 2008
Study CompletionDec 2008
TodayJul 2026
First PostedMar 12, 2008
Enrollment StartDec 1, 2007
Study CompletionDec 1, 2008
TodayJul 2, 2026
Posted 18.3 years ago
Interventions
Esomeprazoledrug
20mg once daily
Esomeprazoledrug
40 mg once daily
Omeprazoledrug
20mg once daily